CHELSEA KROUSE: Open Payments
NPI 1588191332 · FORT WAYNE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$385 in 27 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $54 · 2025 $385
Food & beverage: $385
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $152 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $35 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $34 |
| Lilly USA, LLC | 2 | $31 |
| AstraZeneca Pharmaceuticals LP | 2 | $31 |
| Corium, LLC | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Exact Sciences Corporation | 1 | $15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $15 |
| Amgen Inc. | 1 | $15 |
Products named: UBRELVY, VRAYLAR, Kerendia, CAPLYTA, MOUNJARO, LINZESS, QULIPTA, AIRSUPRA.
Industry payments across IN — which companies pay providers there.
